Search

Your search keyword '"Thomas Hills"' showing total 3 results
Start Over Author "Thomas Hills" Publisher wiley
3 results on '"Thomas Hills"'

1. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: <scp>COVID</scp> ‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell

Author

Jacinta Perram, Duncan Purtill, Ashish Bajel, Jason Butler, Tracey O'Brien, Benjamin Teh, Nicole Gilroy, Phoebe J. Ho, Richard Doocey, Thomas Hills, Travis Perera, Genevieve Douglas, Shanti Ramachandran, Lynette Chee, Judith Trotman, Robert Weinkove, Steven Keogh, Chris Fraser, Tara Cochrane, Anne‐Marie Watson, Peter Diamond, Maya Latimer, Ian Irving, Emily Blyth, Chan Cheah, Theresa Cole, Sam Milliken, Hung Yang, Matthew Greenwood, Peter Bardy, Glen Kennedy, Stephen Larsen, Rachel Conyers, and Nada Hamad

Subjects
Internal Medicine
Published
2023

3. Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID‐19 in New Zealand

Author

Thomas Hills, Richard Beasley, Nicola Arroll, and Eamon Duffy

Subjects
medicine.medical_specialty, viruses, Immunology, Off-label use, medicine.disease_cause, 030226 pharmacology & pharmacy, Health Services Accessibility, Dengue fever, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Chloroquine, Rheumatic Diseases, Pandemic, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Chikungunya, Practice Patterns, Physicians', Intensive care medicine, Coronavirus, Evidence-Based Medicine, business.industry, SARS-CoV-2, virus diseases, Hydroxychloroquine, Evidence-based medicine, Off-Label Use, medicine.disease, United States, COVID-19 Drug Treatment, Antirheumatic Agents, Drug and Narcotic Control, business, medicine.drug, New Zealand
Abstract

The rapid spread of coronavirus disease 2019 (COVID-19) brought into sharp focus the conundrum of how to balance evidence-based prescribing vs empiric treatment with repurposed drugs for a pandemic with a high mortality risk. Initial attention focused on hydroxychloroquine/chloroquine due to evidence of in vitro activity against the novel coronavirus SARS-CoV-2,1 yet the external validity of these data was limited by knowledge that in vitro antiviral activity did not equate to efficacy in randomised controlled trails (RCTs) of hydroxychloroquine/chloroquine treatment for influenza, dengue, chikungunya, and human immunodeficiency virus infection.1.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results